Brevan Howard Capital Management LP Akebia Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 78,121 shares of AKBA stock, worth $132,805. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78,121
Previous 17,148
355.57%
Holding current value
$132,805
Previous $62,000
238.71%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AKBA
# of Institutions
191Shares Held
122MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...